

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

A. For Equity Issues

Name of the issue: **DIPNA PHARMACHEM LIMITED**

1 **Type of issue (IPO/ FPO)** Initial Public Offering (IPO) on SME Platform

2 **Issue size (Rs crore)** Rs. 15.21 Crore

3 **Grade of issue alongwith name of the rating agency** Since the issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018 there is no requirement of appointing a IPO Grading agency.

4 **Subscription level (number of times). If the issue was undersubscribed, please clarify how the funds were arranged.** 2.62 times

5 **QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges (See Clause 35 of the listing agreement)**

(i) allotment in the issue	Nil
(ii) at the end of the 1st Quarter immediately after the listing of the issue	Nil
(iii) at the end of 1st FY	will be updated at the end of 1st F.Y.
(iv) at the end of 2nd FY	will be updated at the end of 2nd F.Y.
(v) at the end of 3rd FY	will be updated at the end of 3rd F.Y.
*Will be updated once the company makes necessary disclosures on the website of BSE Ltd.	

6 **Financials of the issuer (as per the annual financial results submitted to stock exchanges under Regulation 33 of the SEBI(LODR)**

Parameters	(Rs. in Lakhs)		
	1st FY (2022-23)	2nd FY (2023-24)	3rd FY (2024-25)
Income from operations	will be updated at the end of 1st F.Y.	will be updated at the end of 2nd F.Y.	will be updated at the end of 3rd F.Y.
Net Profit for the period			
Paid-up equity share capital			
Reserves excluding revaluation reserves			

7 **Trading status in the scrip of the issuer (whether frequently traded (as defined under Regulation 2 (j) of SEBI (SAST) Regulations, 2011) or infrequently traded/ delisted/ suspended by any stock exchange, etc.)**

(i) at the end of 1st FY	will be updated at the end of 1st F.Y.
(ii) at the end of 2nd FY	will be updated at the end of 2nd F.Y.
(iii) at the end of 3rd FY	will be updated at the end of 3rd F.Y.

8 **Change, if any, in directors of issuer from the disclosures in the offer document (See Clause 34 of the SEBI(LODR)Regulations, 2015**

(i) at the end of 1st FY	will be updated at the end of 1st F.Y.
(ii) at the end of 2nd FY	will be updated at the end of 2nd F.Y.
(iii) at the end of 3rd FY	will be updated at the end of 3rd F.Y.

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

9 Status of implementation of project/ commencement of commercial production (as submitted to stock exchanges under Clause 41 (IV) (e) of the listing agreement)

Objects of the issue (Rs in Lacs)	(Rs. In Lacs)		Actual implementation in implementation, if any
	as disclosed in the offer document	Actual implementation	
Working capital requirement	1110	1110	NA
General Corporate Purposes	365	365	
Issue Related Expenses	45.76	45.76	
TOTAL	1520.76	1520.76	

* Source: BSE filing Reg 32(1) of SEBI(LODR) Reg, 2015

10 Status of utilization of issue proceeds (as submitted to stock exchanges under Clauses 41, 43 and 43A of the listing agreement)

(Rs. In Lacs)	
(i) as disclosed in the offer document	1520.76
(ii) Actual utilization	1520.76
(iii) Reasons for deviation, if any	NA

11 Comments of monitoring agency, if applicable (See Regulation 16 of SEBI (ICDR) Regulations, 2009 read with Clause 43A of the listing agreement)

(a) Comments on use of funds	NA
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds <i>(To be submitted till the time the issue proceeds have been fully utilised)</i>	

12 Price- related data

Issue price (Rs): **38**

Price parameters	At close of listing day 08.09.2022	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day	As at the end of 1st FY after the listing of the issue			As at the end of 2nd FY after the listing of the issue			As at the end of 3rd FY after the listing of the issue		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price	33.4	22.4	21									
Index (of the Designated Stock Exchange):	59,688.22	58191.29	62,626.36									
Sectoral Index (mention the index that has been considered and reasons for considering the same)												

*No sectoral Index available for the Pharmaceutical Industry

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

¹³ **Basis for Issue Price and Comparison with Peer Group & Industry Average** (Source of accounting ratios of peer group and industry average may be indicated; source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)

Accounting ratio	Name of company	As disclosed in the offer document	At the end of 1st FY	At the end of 2nd FY	At the end of 3rd FY
EPS	Issuer:	333.4			
	Peer Group:				
	Earum Pharmaceuticals Limited	0.14			
	A-1 Acid Limited	2.73			
	Industry Avg:	1.435			
P/E	Issuer:	0.11			
	Peer Group:				
	Earum Pharmaceuticals Limited	31.33			
	A-1 Acid Limited	107.51			
RoNW	Industry Avg:	69.42			
	Issuer:	67.12			
	Peer Group:				
	Earum Pharmaceuticals Limited	0.81			
NAV per share based on balance sheet	A-1 Acid Limited	6.79			
	Industry Avg:	3.8			
	Issuer:	496.74			
	Peer Group:				
	Earum Pharmaceuticals Limited	23.51	will be updated at the end of 1st F.Y.	will be updated at the end of 2nd F.Y.	will be updated at the end of 3rd F.Y.
	A-1 Acid Limited	40.21			
	Industry Avg:	31.86			

¹⁴ **Any other material information**

Nil